NEW YORK – The combination of Bristol Myers Squibb's anti-PD-1 inhibitor nivolumab (Opdivo) and its anti-CTLA-4 therapy ipilimumab (Yervoy) demonstrated modest activity in metastatic, castration-resistant prostate cancer (mCRPC) patients, according to recently published preliminary data from the CheckMate-650 trial.
However, exploratory biomarker analysis in the same study suggested that patients with higher tumor mutational burden may potentially derive greater benefit from the regimen than those with lower TMB levels and should be investigated further.